September 30, 2016 12:39 PM Eastern Standard Time ST. HELIER, Jersey, Sept. 30, 2016 (GLOBE NEWSWIRE) — In a press release issued under the same headline earlier today by Novocure, Ltd. (Nasdaq:NVCR), please note that the first paragraph should say “the three and nine months ended Sept. 30, 2016” rather than “the three and six …
September 30, 2017 12:00 AM Eastern Standard Time ST. HELIER, Jersey, Sept. 30, 2016 (GLOBE NEWSWIRE) — Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss …
Guidelines provide a framework for using the NovoTAL System to optimize Tumor Treating Fields intensity in Optune patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that CNS Oncology published Tumor Treating Fields (TTFields) treatment planning and patient follow-up guidelines, providing a standardized resource for the use of the NovoTAL System to optimize TTFields intensity in …
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Executive Chairman William Doyle will present at the New York Academy of Sciences’ 13th Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms on Friday, Sept. 23, 2016. Mr. Doyle’s presentation “Tumor Treating Fields – A Novel Cancer Therapy Utilizing Alternating Electric Fields” will focus …
Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that two independent institutions published scientific research on Tumor Treating Fields (TTFields), representing increasing external interest from the scientific community in Novocure’s innovative, proprietary therapy. The published data support Novocure’s existing body of …
Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide ST. HELIER, JERSEY–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that long-term survival analysis of the full 695 patient dataset from the phase 3 pivotal EF-14 trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM) …
Novocure has completed enrollment of a phase 2 pilot trial in ovarian cancer and will present data on Dec. 12, 2016 ST. HELIER, JERSEY–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that data showing Tumor Treating Fields (TTFields) in combination with paclitaxel is therapeutically effective against ovarian cancer cells in vitro and in vivo has been published …
